

Product Specification Sheet

**Human Recombinant Purified Leptin Triple mutant Antagonist Protein**

□ **Cat #** LEP21-TM-50    Human Recombinant (E.Coli) Purified Leptin Triple mutant Antagonist Protein    **SIZE:** 50 ug

Obesity, a common nutritional disorder, is associated with diabetes, hypertension, hyperlipidemia, cancer and many other health related problems. At least five genes, Obese (**ob**), diabetes (**db**), fat (**fat**), agouti yellow (**Ay**), and tubby (**tub**) have been linked to obesity. Recently, **Ob genes** (mouse and human) have been cloned. Obese gene encodes an adipocyte-tissue derived secreted **Ob protein/Leptin** (167 amino acid, ~16 kDa) that controls body weight homeostasis. Exogenous administration of recombinant Ob protein can reduce food intake and body weight. However, Ob protein had no effect in db/db mice suggesting a defect in leptin signaling mechanism. Purified human Leptin (1-10 ug/gm of body weight; daily i.p injections for 14 days) has been shown to be biologically active in reducing body weight and food consumption in ob/ob and NZO mice (2).

Recently, Salomon et al (3) reported the development of a series of recombinant leptin analogs in which alanine was substituted for amino acids expressed in positions (39-41, **L39A/D40A/F41A** ; **triple mutants**) or 39-42 (**L39A/D40A/F41A/I42A**; **quadruple mutants**) of wild-type leptin. Leptin mutant showed normal binding to leptin receptor. All leptin mutants formed a 1:1 complex with chicken leptin binding domain, (chLBD) and bound chLBD or membrane-embedded leptin receptor with affinity identical to WT leptins. Muteins were devoid of any biological activity in several bioassays but were potent competitive antagonists. However, these substitutions resulted in compounds with antagonist effects on leptin induced transcriptional changes observed in a heterologous cell system expressing the long form of the leptin receptor (Ob-Rb). Daily intracerebroventricular co-injection of Leptin triple mutant with exogenous leptin significantly attenuated leptin induced reduction of 48-h food-intake and body weight (4).

**Source and Properties of Leptin**

Leptin is ~16 kDa, adipocyte derived, secreted protein (1). Recombinant human leptin, containing 146 amino and an additional Ala at N-terminus acids was mutated, resulting in **L39A/D40A/F41A, triple mutants** was cloned, expressed in E. Coli and purified (>95% by SDS-PAGE). Recombinant leptin mutant has a predicted mol. Mass of ~16 kDa. The identity of protein has been confirmed by N-Terminal sequence analyses. Endotoxin level in the final preparation is less than 10 pg/μg of Leptin.

Purified leptin protein has <5% aggregates or dimers. The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Val-Pro-Ile-Gln.

**Biological activity:**

HumanLEP triple antagonist is capable of inhibiting leptin-induced proliferation of BAF/3 cells stably transfected with the long form of human leptin receptor. It also inhibits various leptin effects in several in vitro bioassays.

**Form & Storage**

Recombinant Leptin is supplied in either isotonic PBS solution (1 mg/ml or lot sp conc stated on the vial) or Lyophilized in 0.004 mM NaHCO<sub>3</sub> with no preservative.

Reconstitute the lyophilized hLEP mutant in sterile 0.4% NaHCO<sub>3</sub> adjusted to pH 8-9, not less than 100μg/ml, which can then be further diluted to other aqueous solutions. It may be desirable to add protease-free BSA or human serum albumin (0.1%) and solution sterile filtered. It is stable at 4oC for 2-4 weeks and 3-6 months at -70oC. Avoid repeated freeze and thaw and store in suitable size aliquots.

**General References:**

(1)Zhang, Y et al (1994) Nature 372, 425-431; (2) Pelleymounter MA et al (1995) Science 269, 540; (3) Salomon G (2006) Protein Exp. Purif. 47, 128-136; Solomon G (2006) Ann NY Acad Sci. 1091, 531-539; (4) Peters JH (2007) Endocrinol. in press.

**List of publications using ADI Leptin** (updates at the web site).

Iida M et al, 1998    Regulatory peptides 277, 77, 141-146  
Tatsuya, Y, 1997    Diabetes. 46(6):1077-1080.

This product is for In vitro research use only. NOT FOR DRUG USE.

**Related material available from ADI**

LEP11-R-1000	Mouse Recombinant Purified Leptin Protein
LEP14-R1000	Human Recombinant Purified Leptin Protein
LEP14-S	Anti-Human Leptin Protein antiserum # 2
LEP14-M	Monoclonal Anti-Human Leptin Protein
LEP14-R-1000	Rat Recombinant Purified Leptin Protein
LEP14-R-50	Ovine Recombinant Purified Leptin Protein
LEP15-R-50	Bovine Recombinant Purified Leptin Protein
LEP16-R-50	Porcine Recombinant Purified Leptin Protein
LEP17-R-50	Horse Recombinant Purified Leptin Protein
LEP18-R-50	Chicken Recombinant Purified Leptin Protein
LEP19-R-50	Dog Recombinant Purified Leptin Protein
LEP20-R-50	Rabbit Recombinant Purified Leptin Protein
LEP21-TM-100	Human Leptin Triple Antagonist Protein
LEP22-QM-100	Human Leptin Quadruple Antagonist Protein
LEP23-TM-100	Mouse Leptin Triple Antagonist Protein
LEP24-TM-100	Rat Leptin Triple Antagonist Protein
LEP25-TM-100	Ovine Leptin Triple Antagonist Protein
LEP26-QM-100	Ovine Leptin Quadruple Antagonist Protein
LEPBP11-S	Anti-Human Leptin binding Protein antiserum
LEPBP15-R-100	Human Leptin binding Protein
LEPBP16-R-100	Chicken Leptin binding Protein

Antibodies to Leptin (OBRa/b receptors), **Leptin ELISA kits**  
Antibodies to Adiponectin (**Acrp30**), **Resistin and ELISA kits**

LEP21-TM-50

160822SV

**India Contact:**

**Life Technologies (India) Pvt. Ltd.**

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444

Email: [customerservice@lifetechindia.com](mailto:customerservice@lifetechindia.com)    Website: [www.lifetechindia.com](http://www.lifetechindia.com)